Skip to main content
. Author manuscript; available in PMC: 2016 Sep 15.
Published in final edited form as: Cancer. 2015 May 29;121(18):3298–3306. doi: 10.1002/cncr.29480

Figure 2.

Figure 2

Kaplan-Meier estimates of progression free survival (PFS) in (A) intent-to-treat, (B) EGFR wild type, (C) elevated baseline PGEM, (D) low baseline PGEM. HR, hazard ratio; PGEM, urine prostaglandin E metabolite.